Product
somapacitan
1 clinical trial
2 indications
Indication
Growth Hormone DisorderIndication
Growth Hormone DeficiencyClinical trial
A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone DeficiencyStatus: Recruiting, Estimated PCD: 2024-08-26